




RealRate

## PHARMACEUTICAL 2018

Strongbridge Biopharma plc  
Rank 271 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)

The relative strengths and weaknesses of Strongbridge Biopharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Strongbridge Biopharma plc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Strongbridge Biopharma plc is the variable Net Income, reducing the Economic Capital Ratio by 146% points.

The company's Economic Capital Ratio, given in the ranking table, is -431%, being 154% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	60,813
Cost of Goods Sold	0
Intangible Assets	42,411
Liabilities, Current	12,479
Liabilities, Non-Current	37,794
Other Assets	686
Other Compr. Net Income	0
Other Expenses	28,999
Other Liabilities	65,566
Other Net Income	-37,970
Property and Equipment	15
Research and Development	17,268
Revenues	7,046
Selling, General and Administrative Expense	36,292

Output Variable	Value in 1000 USD
Assets	103,925
Liabilities	115,839
Expenses	82,559
Stockholders Equity	-11,914
Net Income	-113,483
Comprehensive Net Income	-113,483
Economic Capital Ratio	-431%